Many people are also unaware that early clinical trials for their MS drug has shown to stop progession of MS. All other treatments to date only slow progression.
CEO Rik Deitsch is a very class act and a well respected Biotech expert. Rik is really excited about the Cobroxin cash flow funding some explosive clinical trial developments.
News 
Market Data 
Discover 
AI
